Clinical Trial Update: BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of Bacillus Calmette-Guérin (BCG) with interferon alfa-2b for bladder cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Bladder Cancer | Phase 2 | Status: COMPLETED